Fuji Pharma and Alvotech enter exclusive partnership agreement to commercialise biosimilars

Nov 19, 2018

Fuji Pharma and Alvotech announce exclusive partnership agreement for the commercialisation of Alvotech’s biosimilars in Japan. Fuji Pharma will be responsible for the registration and commercialisation of products, while Alvotech will be responsible for development and supply.

Print Page Mail Article